As shown in Fig. 2a,b, the capacity of CAR4 T cells to control tumor burden in the bone marrow and in the blood was largely reduced when IFN-γ−/− CAR4 T cells were used for treatment. The gene discussed is IFNG; the disease is neoplasm.